title: Severe oral mucositis associated with cancer therapy: impact on oral functional status and quality of life.
abstract: OBJECTIVE
  This study determined the incidence of severe oral mucositis (OM), patients' self-reported moderate and severe oral symptoms, and change of quality of life (QoL), as well as examined whether OM severity and pain scores predicted the impairment of oral function and QoL.
  
  
  METHODS
  A multicenter approach was used and 137 patients treated with stomatotoxic chemotherapy (45%), high-dose myeloablative chemotherapy with or without concomitant total body irradiation (12%), head and neck irradiation with or without concomitant chemotherapy (44%) completed the OM-specific QoL measure (OMQoL) once or twice weekly over a 4- or 10-week period, along with concurrent measures of OM using WHO Mucositis Grading System and oral symptoms using 10 cm visual analog scale.
  
  
  RESULTS
  The incidence of severe OM was 50% (n = 68). About 77-80% of patients with severe OM reported moderate or severe mouth or throat pain, and 66-78% reported moderate or severe oral functional problems. The oral symptoms peak and area-under-the-curve (AUC) scores of patients with severe OM (peak 5.6 to 6.8; AUC 3.8 to 5.2) were significantly higher than those without OM and those with mild OM (p < 0.01). The OMQoL subscales peak and AUC scores of patients with severe OM (peak 47.9 to 62.1; AUC -40.1 to -25.8) were significantly lower than those without OM and those with mild OM (p < 0.01). Of those with severe OM, 88-94% had a drop in the OMQoL subscale scores to at least 10 points from the baseline. Pain resulting from OM, in particular throat pain, is most predictive of oral functional impairment (standardized β = 0.53-0.83).
  
  
  CONCLUSIONS
  Severe OM can cause profound pain and oral functional incapability and clinical significant impairment of QoL.
authors.affiliation: Faculty of Medicine, The Nethersole School of Nursing, The Chinese University of Hong Kong, Room732, Esther Lee Building, Sha Tin, Hong Kong, NT, China. kariskwong@cuhk.edu.hk
authors.forename: Karis Kin-Fong
authors.initials: KK
authors.lastname: Cheng
authors.forename: S F
authors.initials: SF
authors.lastname: Leung
authors.forename: Raymond H S
authors.initials: RH
authors.lastname: Liang
authors.forename: Josepha W M
authors.initials: JW
authors.lastname: Tai
authors.forename: Rebecca M W
authors.initials: RM
authors.lastname: Yeung
authors.forename: David R
authors.initials: DR
authors.lastname: Thompson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy*; D010146:Pain / Q000209:etiology; D011788:Quality of Life; D012720:Severity of Illness Index; D013280:Stomatitis / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents